Modified Rankin Stroke Scale
0 - No symptoms at all.
1 - No significant disability despite symptoms; able to carry out all usual duties and activities.
2 - Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance.
3 - Moderate disability; requiring some help, but able to walk without assistance.
4 - Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance.
5 - Severe disability: bedridden, incontinent, and requiring constant nursing care and attention.

Social Security Act section 1861(r) (1)


Topol, editor, 2002.

Ibid.

Ibid.

Schnieder et al., 2003.

http://www.americanheart.org/presenter.jhtml?identifier=4742

Schnieder et al., 2003.

O’Rourke et al., 2004.


Barnett et al., 1999.


FDA is not bound by this Advisory Panel’s recommendations.
Letter dated August 30, 2004 from Center for Devices and Radiological Health of the Food and Drug Administration (FDA) to Guidant Corporation

Federal Register Vol 68 No.187 September 26, 2003 p55,636


Alberts, 2001

Ibid.

Brooks et al., 2004.

Ibid.


Ibid.


Yadav et al., 2004.


Gray, ACC meeting 2004.

White et al. submission to CMS, 2004

Hopkins, TCT meeting 2004.
37 Ibid.
38 Ibid.
40 Cremonesi et al., 2003.
41 Ramee, TCT meeting 2004.
42 Reimers et al., 2004.
43 Roubin et al., 2001.
45 ECST investigators, 1998.
46 Ibid.
47 ACAS committee, 1995.
50 Ibid.
51 NASCET collaborators, 1991.
52 Barnett et al., 1998.
53 Inzitari et al., 2000.
54 Brott et al., 2004.
55 Ibid.
56 Connors et al., 2004.
57 Coward et al., 2004
58 Ibid.
59 Creager et al., 2004.
60 O’Rourke et al., 2004.
61 Halm et al., 2004.
62 AHA, 1995

63 Attachment 1: “Qualifications and Training Requirements” Quality Improvement Guidelines for the performance of Cervical Carotid Angioplasty and Stent Placement” Letter from SIR dated July 26, 2004 to Dr. Steve Phurrough

64 Letter from SVMB, SCAI, SVS, and ACC dated July 20, 2004 to Dr. Sean Tunis.

65 July 21, 2004 ASITN/CMS meeting slides

66 Longstreth WT Jr, Shemanski L, Lefkowitz D, Et al

67 Letter from AAN, AANS, ASITN, ASNR, CNS, AANS/CNS Cerebrovascular section, and SIR dated August 23, 2004 to Dr. Steve Phurrough

68 Ouriel, presentation at FDA panel meeting 2004.


70 CURE trial, 2001.


73 NASCET collaborators, 2002.

74 Ibid.

75 Barnett et al., 1998

76 ECST group, 1998.

77 Ibid.

78 Ouriel, presentation at FDA panel meeting 2004.


O’Rourke et al., 2004.


Barnett et al., 1998.


Coward et al., 2004.

ACAS committee, 1995.


O’Rourke et al., 2004.

ACAS committee, 1995.


Ibid.


Halm et al., 2003.

Brott et al., 2004.

O’Rourke et al., 2004.


Ouriel, presentation at FDA panel meeting 2004.

Brott et al., 2004.


SAPPHIRE data submitted by Cordis.

Yurdakul et al., 2004.

Connors et al., 2004.


Social Security Act section 1861(r) (1)

Connors et al., 2004.

Creager et al., 2004.

Medicare NCD Manual section 20.7.